The FDA granted accelerated approval to the programmed death receptor-1 (PD-1)-blocking antibody dostarlimab-gxly (Jemperli, GlaxoSmithKline) for adults with mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or after a platinum-containing regimen.
The agency also approved the VENTANA MMR RxDx Panel (Roche) to identify patients with advanced or recurrent endometrial cancer who are eligible for treatment with dostarlimab.